| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| Targets |
VHL
|
|---|---|
| ln Vitro |
ZXH-4-130 TFA (100 nM; pretreatment for 2 hours; subsequent treatment with 1 μM pomalidomide for 96 hours) has a statistically significant preventative effect [1] that greatly inhibits the cytotoxicity of pomalidomide (1 μM). In MM1.S cells, ZXH-4-130 TFA (50 nM pretreatment) prevents GSPT1 degradation caused by CC-885 [1]. ZXH-4-130 (100 nM) TFA causes nearly total CRBN degradation, but only partially blocks THAL-SNS-032's activity on CDK9 [1]. This is followed by a 6-hour THAL-SNS-032 treatment.
|
| References |
| Molecular Formula |
C48H59F3N6O11S
|
|---|---|
| Molecular Weight |
985.08
|
| Exact Mass |
984.391
|
| CAS # |
2711006-67-4
|
| Related CAS # |
ZXH-4-130;2711006-66-3
|
| PubChem CID |
162640901
|
| Appearance |
Off-white to gray solid powder
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
20
|
| Heavy Atom Count |
69
|
| Complexity |
1700
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
N1=CSC(C2C=CC(=CC=2)CNC([C@@H]2C[C@H](CN2C(=O)[C@H](C(C)(C)C)NC(CCCCCCCCCCOC2=CC=CC3=C2C(=O)N(C2CCC(NC2=O)=O)C3=O)=O)O)=O)=C1C.OC(=O)C(F)(F)F
|
| InChi Key |
QKDOGOBHFHCHMX-YYRHATPXSA-N
|
| InChi Code |
InChI=1S/C46H58N6O9S.C2HF3O2/c1-28-39(62-27-48-28)30-19-17-29(18-20-30)25-47-41(56)34-24-31(53)26-51(34)45(60)40(46(2,3)4)49-36(54)16-11-9-7-5-6-8-10-12-23-61-35-15-13-14-32-38(35)44(59)52(43(32)58)33-21-22-37(55)50-42(33)57;3-2(4,5)1(6)7/h13-15,17-20,27,31,33-34,40,53H,5-12,16,21-26H2,1-4H3,(H,47,56)(H,49,54)(H,50,55,57);(H,6,7)/t31-,33?,34+,40-;/m1./s1
|
| Chemical Name |
(2S,4R)-1-[(2S)-2-[11-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyundecanoylamino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide;2,2,2-trifluoroacetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~170 mg/mL (~172.57 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 4.25 mg/mL (4.31 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 42.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0151 mL | 5.0757 mL | 10.1515 mL | |
| 5 mM | 0.2030 mL | 1.0151 mL | 2.0303 mL | |
| 10 mM | 0.1015 mL | 0.5076 mL | 1.0151 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
